Status:
NOT_YET_RECRUITING
Impact of Hepatitis B Immunoglobulins in Patients With Chronic Hepatitis B on Hepatocellular Carcinoma - a Proof of Concept Study
Lead Sponsor:
Medical University of Graz
Conditions:
Hepatocellular Carcinoma
HBV
Eligibility:
All Genders
19-80 years
Phase:
NA
Brief Summary
In the current literature, infection with the hepatitis B virus (HBV) is described as one of the main risk factors for the development of hepatocellular carcinoma (HCC). According to the current stud...
Eligibility Criteria
Inclusion
- Patients ≥ 19 years and ≤ 80 of age
- HBsAg-positive HCC-patients scheduled for resection in ≥6 weeks or HBsAg-positive HCC- patients listed for LT
- Ability of subjects to understand character and individual consequences of the clinical trial
- Written informed consent must be available before enrolment in the trial
Exclusion
- Clinically significant illness (other than HBV) or any other major medical disorder that, in the opinion of the investigator, may interfere with subject treatment
- No eligibility for resection / LT
- Concurrent any other malignancy
- Co-infection with hepatitis C virus (defined as HCV RNA positive, HCV RNA-negative/anti-HCV-positive patients can be included) and/or human immunodeficiency virus (HIV)
- Clinical hepatic decompensation
- Allergy to HBIG
- Pregnant, lactating patients
Key Trial Info
Start Date :
November 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT05293158
Start Date
November 1 2024
End Date
June 1 2026
Last Update
January 18 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.